[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) director and CEO Neil Kumar reported insider sales under a Rule 10b5-1 plan. On 08/20/2025 the reporting person sold a total of 26,156 shares in two transactions (25,728 and 428 shares) at weighted average prices shown in the filing. Following those sales the filing reports 223,518 and 223,090 shares beneficially owned in the two reported lines, held directly. The report also discloses indirect holdings of 4,718,447 shares via the Kumar Haldea Revocable Trust and 915,686 shares via the Kumar Haldea Family Irrevocable Trust, of which the reporting person is a co-trustee. The transactions were effected pursuant to a 10b5-1 sales plan adopted March 31, 2025. The Form 4 was signed by an attorney-in-fact on 08/22/2025.

Positive

• Transactions executed under a Rule 10b5-1 plan, indicating prearranged sales and procedural compliance
• Full disclosure of indirect trust holdings (4,718,447 and 915,686 shares) and direct post-sale holdings

Negative

• Insider sold 26,156 shares on 08/20/2025, which may be perceived negatively by some investors even though planned
• Post-sale direct holdings reduced to ~223k shares in the reported lines (while significant indirect holdings remain)

Insights

Financial Analyst

TL;DR: CEO/director executed prearranged sales totaling 26,156 shares under a 10b5-1 plan; overall ownership remains concentrated via trusts.

The filing discloses two reported dispositions on 08/20/2025 totaling 26,156 shares sold under a Rule 10b5-1 plan adopted 03/31/2025. The reported weighted average prices are provided in the footnotes for the respective sale ranges. Post-transaction direct beneficial ownership is reported around ~223k shares on the disclosed lines, while significant indirect holdings of 4,718,447 and 915,686 shares are held through named trusts where the reporting person is co-trustee. From a financial oversight perspective this is a routine, preplanned disposition with clear disclosure of trust holdings.

Corporate Governance Expert

TL;DR: Insider sales were executed under a documented 10b5-1 plan and properly reported; large trust holdings are disclosed.

The Form 4 indicates compliance with Rule 10b5-1 procedures, as the reporting person checked the box indicating the transactions were made pursuant to such a plan. The filing includes required footnote detail on weighted average sale price ranges and disclaims beneficial ownership of trust-held shares except to the extent of any pecuniary interest. The report is signed by an attorney-in-fact, consistent with permitted filing practices.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kumar Neil

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/20/2025		S(1)		25,728	D	$48.8125(2)	223,518	D
Common Stock	08/20/2025		S(1)		428	D	$49.2504(4)	223,090	D
Common Stock								4,718,447	I	By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.(3)
Common Stock								915,686	I	By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

2. Represents the weighted average sale price of the shares sold from $48.22 to $49.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

3. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

4. Represents the weighted average sale price of the shares sold from $49.22 to $49.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

	/s/ Laura Woodhead, Attorney-in-Fact	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Neil Kumar report on Form 4 for BBIO?

The filing shows two dispositions on 08/20/2025 totaling 26,156 shares (25,728 and 428 shares) sold under a Rule 10b5-1 plan.

Were the sales executed under a prearranged plan?

Yes. The reporting person indicated the transactions were made pursuant to a Rule 10b5-1 sales plan adopted March 31, 2025.

How many BBIO shares does the reporting person indirectly own via trusts?

The report discloses indirect holdings of 4,718,447 shares (Kumar Haldea Revocable Trust) and 915,686 shares (Kumar Haldea Family Irrevocable Trust).

When were the transactions reported and who signed the Form 4?

The transactions occurred on 08/20/2025 and the Form 4 was signed by Laura Woodhead, Attorney-in-Fact on 08/22/2025.

What prices were the shares sold at according to the filing?

Footnotes report weighted average sale price ranges: $48.22–$49.20 per share for one set of sales (weighted avg shown as $48.8125) and $49.22–$49.26 per share for the other (weighted avg shown as $49.2504).